Survival by histology among patients with bone and soft tissue sarcoma who undergo metastasectomy: protocol for a systematic review and meta-analysis.
Bone sarcoma
Metastasectomy
Metastasis
Outcome
Pediatric sarcoma
Resection
Soft tissue sarcoma
Survival
Journal
Systematic reviews
ISSN: 2046-4053
Titre abrégé: Syst Rev
Pays: England
ID NLM: 101580575
Informations de publication
Date de publication:
20 08 2020
20 08 2020
Historique:
received:
03
09
2019
accepted:
05
08
2020
entrez:
22
8
2020
pubmed:
21
8
2020
medline:
25
6
2021
Statut:
epublish
Résumé
Metastasectomy is performed on a select cohort of patients with advanced and/or recurrent bone and soft tissue sarcomas because of the potential for long term relapse free and overall survival associated with the procedure. However, the evidence supporting metastasectomy is difficult to summarize without a systematic examination of existing literature. The objective of this systematic review will be to examine survival among both adults and children with advanced and recurrent bone and STS who undergo metastasectomy. We designed and registered a study protocol for a systematic review and meta-analysis. We will include data from survival studies (e.g., randomized trials, cohort studies, routine case registries, and case control) conducted in children and adults with advanced and recurrent bone and soft tissue sarcoma who undergo metastasectomy. The primary outcome will be overall survival. Secondary outcomes will be 30-day post-operative mortality, recurrence-free survival, time off systemic therapy, and patient-reported outcomes including quality of life end points where available. Literature searches will be performed in multiple electronic databases including Ovid MEDLINE ® (1946 to present), Ovid EMBASE (1974 to present), Web of Science, and Cochrane Library. Grey literature will be identified through searching references, conference abstracts, Papers First, and Google Scholar. Two investigators will independently screen all citations, full-text articles, and abstract data. Full-text articles selected for analysis will be assessed for quality and risk of bias. If feasible, we will conduct a random effects meta-analysis. Estimates will be stratified according to histology comparing survival based on organ of metastasectomy. Additional analysis will be conducted to explore the potential sources of heterogeneity according to various patient, disease, and treatment characteristics (e.g., metastasis status, age, disease burden, and concomitant interventions). This systematic review and meta-analysis will identify, evaluate, and integrate data on survival of metastasectomy of bone and soft tissue sarcoma by organ of metastasis. Our findings may have implications for clinicians, patients, and their families when considering selection for resection of oligometastatic disease in de novo, or recurrent bone and soft tissue sarcoma. Implications for future research will be identified to improve the outcomes of these complex patients. PROSPERO CRD42019126906.
Sections du résumé
BACKGROUND
Metastasectomy is performed on a select cohort of patients with advanced and/or recurrent bone and soft tissue sarcomas because of the potential for long term relapse free and overall survival associated with the procedure. However, the evidence supporting metastasectomy is difficult to summarize without a systematic examination of existing literature. The objective of this systematic review will be to examine survival among both adults and children with advanced and recurrent bone and STS who undergo metastasectomy.
METHODS
We designed and registered a study protocol for a systematic review and meta-analysis. We will include data from survival studies (e.g., randomized trials, cohort studies, routine case registries, and case control) conducted in children and adults with advanced and recurrent bone and soft tissue sarcoma who undergo metastasectomy. The primary outcome will be overall survival. Secondary outcomes will be 30-day post-operative mortality, recurrence-free survival, time off systemic therapy, and patient-reported outcomes including quality of life end points where available. Literature searches will be performed in multiple electronic databases including Ovid MEDLINE ® (1946 to present), Ovid EMBASE (1974 to present), Web of Science, and Cochrane Library. Grey literature will be identified through searching references, conference abstracts, Papers First, and Google Scholar. Two investigators will independently screen all citations, full-text articles, and abstract data. Full-text articles selected for analysis will be assessed for quality and risk of bias. If feasible, we will conduct a random effects meta-analysis. Estimates will be stratified according to histology comparing survival based on organ of metastasectomy. Additional analysis will be conducted to explore the potential sources of heterogeneity according to various patient, disease, and treatment characteristics (e.g., metastasis status, age, disease burden, and concomitant interventions).
DISCUSSION
This systematic review and meta-analysis will identify, evaluate, and integrate data on survival of metastasectomy of bone and soft tissue sarcoma by organ of metastasis. Our findings may have implications for clinicians, patients, and their families when considering selection for resection of oligometastatic disease in de novo, or recurrent bone and soft tissue sarcoma. Implications for future research will be identified to improve the outcomes of these complex patients.
SYSTEMATIC REVIEW REGISTRATION
PROSPERO CRD42019126906.
Identifiants
pubmed: 32819423
doi: 10.1186/s13643-020-01445-z
pii: 10.1186/s13643-020-01445-z
pmc: PMC7441630
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
189Références
Curr Oncol. 2020 Feb;27(Suppl 1):25-33
pubmed: 32174755
Am J Clin Oncol. 2018 Jul;41(7):681-686
pubmed: 27819879
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Ann Surg. 2000 Apr;231(4):500-5
pubmed: 10749609
Am J Clin Oncol. 2001 Apr;24(2):198-200
pubmed: 11319298
Ann Oncol. 2018 Apr 1;29(4):857-871
pubmed: 29432564
Eur J Cancer. 2013 Feb;49(3):684-95
pubmed: 23079473
BMJ Open. 2012 Oct 08;2(5):
pubmed: 23048062
Cancer. 1996 Feb 15;77(4):675-82
pubmed: 8616759
Trials. 2007 Jun 07;8:16
pubmed: 17555582
Thorac Cardiovasc Surg. 2006 Mar;54(2):120-3
pubmed: 16541354
Ann Surg. 1999 May;229(5):602-10; discussion 610-2
pubmed: 10235518
Clin Epidemiol. 2013 May 16;5:147-62
pubmed: 23700373
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
J Pediatr Hematol Oncol. 2008 Jun;30(6):425-30
pubmed: 18525458
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Semin Surg Oncol. 1990;6(5):297-302
pubmed: 2237090
Semin Oncol. 2008 Apr;35(2):134-46
pubmed: 18396199